Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
Study Type: Treatment
Phase: II
NCTID: NCT06368817
Principal Investigator:
Keith August
A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib NSC 748727 in Newly Diagnosed or Previously Untreated Low-Grade Glioma LGG Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 NF1
Study Type: Treatment
Phase: III
NCTID: NCT04166409
Principal Investigator:
Keith August
Advancing Treatment for Pediatric Craniopharyngioma: Prospective Pilot Study Identifying Clinically Relevant Biological Targets for Medical Therapy
Study Type: Other
Phase: Feasibility/Pilot
NCTID: NCT03610906
Principal Investigator:
Kevin Ginn
A Phase 1/2 Trial of Selinexor KPT-330 and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma DIPG and High-Grade Glioma HGG
Study Type: Treatment
Phase: I/II
NCTID: NCT05099003
Principal Investigator:
Keith August
A Multicenter Observational Study of GammaTileTM Surgically Targeted Radiation Therapy STaRT in Intracranial Brain Neoplasms
Study Type: Other
Phase: IV
NCTID: NCT04427384
Principal Investigator:
Roukoz Chamoun
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers ICONIC
Study Type: Treatment
Phase: II
NCTID: NCT03866382
Principal Investigator:
Elizabeth Wulff
A Phase I Trial Combining Triapine with Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Study Type: Treatment
Phase: I
NCTID: NCT06860594
Principal Investigator:
Tolga Tuncer
NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine DFMO
Study Type: Prevention
Phase: II
NCTID: NCT02679144
Principal Investigator:
Kevin Ginn
Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma
Study Type: Treatment
Phase: II
NCTID: NCT04696029
Principal Investigator:
Kevin Ginn
A Phase 3, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in participants with isocitrate dehydrogenase 1 IDH1-mutant glioma
Study Type: Treatment
Phase: II
NCTID: NCT05303519
Principal Investigator:
Tolga Tuncer